| human | Q5 |
| P496 | ORCID iD | 0000-0002-1337-7267 |
| P735 | given name | Marta | Q846741 |
| Marta | Q846741 | ||
| P106 | occupation | researcher | Q1650915 |
| Q47613536 | Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older |
| Q92182468 | Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial |
| Q91305081 | Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial |
| Q28567709 | Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF |
| Q46248547 | Results of a Safety Pooled Analysis of an Adjuvanted Herpes Zoster Subunit Vaccine in More than 14,500 Participants Aged 50 Years or Older. |
| Q38597522 | Results on exposure during pregnancy from a pregnancy registry for AS04-HPV-16/18 vaccine. |
| Q92762679 | Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials |
| Q39790449 | The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. |
Search more.